Strides Pharma Science’s reborn injectables business will be going strong in several markets by the end of 2019, founder and managing director Arun Kumar has told analysts, adding that the company’s robust second-quarter earnings performance – in which earnings before interest, tax, depreciation and amortization rocketed 210% year-on-year – has shown that being a corporate “contrarian” pays off.
Kumar said Strides, which focuses on tough-to-make niche products sold in over 100 countries, was very “excited about rebuilding this...




